These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 28122118)

  • 21. Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.
    Athyros VG; Sachinidis AG; Zografou I; Simoulidou E; Piperidou A; Stavropoulos N; Karagiannis A
    Curr Pharm Des; 2018; 24(46):5542-5547. PubMed ID: 30848186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study.
    Pergola PE; Spiegel DM; Warren S; Yuan J; Weir MR
    Am J Nephrol; 2017; 46(4):323-332. PubMed ID: 29017162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
    Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium zirconium cyclosilicate (Lokelma) for hyperkalemia.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):197-199. PubMed ID: 30653476
    [No Abstract]   [Full Text] [Related]  

  • 27. Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis.
    Shrestha DB; Budhathoki P; Sedhai YR; Baniya R; Cable CA; Kashiouris MG; Dixon DL; Kidd JM; Adhikari Y; Marasini A; Bhandari S
    Curr Ther Res Clin Exp; 2021; 95():100635. PubMed ID: 34367383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential New Agents for the Management of Hyperkalemia.
    Packham DK; Kosiborod M
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):19-31. PubMed ID: 26156040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient.
    Ash SR; Singh B; Lavin PT; Stavros F; Rasmussen HS
    Kidney Int; 2015 Aug; 88(2):404-11. PubMed ID: 25651363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials.
    Amin AN; Menoyo J; Singh B; Kim CS
    BMC Nephrol; 2019 Dec; 20(1):440. PubMed ID: 31791288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Agents for the Prevention and Management of Hyperkalemia.
    McCullough PA; Costanzo MR; Silver M; Spinowitz B; Zhang J; Lepor NE
    Rev Cardiovasc Med; 2015; 16(2):140-55. PubMed ID: 26198561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting.
    Di Palo KE; Sinnett MJ; Goriacko P
    JAMA Netw Open; 2022 Jan; 5(1):e2145236. PubMed ID: 35080601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
    Rafique Z; Peacock WF; LoVecchio F; Levy PD
    Expert Opin Pharmacother; 2015; 16(11):1727-34. PubMed ID: 26159448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials.
    Piña IL; Yuan J; Ackourey G; Ventura H
    Prog Cardiovasc Dis; 2020; 63(5):656-661. PubMed ID: 33007353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials.
    Haller H; Bianchi S; McCafferty K; Arthur S; Quinn CM; Budden J; Weir MR
    Kidney360; 2022 Dec; 3(12):2019-2026. PubMed ID: 36591361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients.
    Sullivan E; Ruegger M; Dunne I; Sutaria N; Towers WF
    Am J Health Syst Pharm; 2023 Sep; 80(18):1238-1246. PubMed ID: 37335862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.